1518548473917939712

At this year’s #Tandem22 Meetings, we are proud to present several posters on the Phase 3 study of omidubicel and its potential impact on the patient experience and unmet needs that exist for patients with hematologic malignancies. Latest news here: https://t.co/lu9MO9snFP https://t.co/9q2zSqYdkN

Send us a message